Ulrich Lücking

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 10

Top Venues

Chemistry (Weinheim an der Bergstrasse, Germany)

Journal of medicinal chemistry

ChemMedChem

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Amjad Ali, Marcus Bauser, Sophie M Bertrand, Wesley Blackaby, Christoph Boss, Martin Bossart, Adrian Hall, Hayley Binch, Werngard Czechtizky, Harrie J M Gijsen, Helmut Haning, Ingo V Hartung, Paul Kilburn, Gilbert Lassalle, Ulrich Lücking, Jürgen Mack, Martin Missbach, Leena Otsomaa, Antoni Torrens, Michael Wagner, Magnus Walter, Harald Weinstabl, Luc van Hijfte, Franz von Nussbaum
European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe. ChemMedChem (2023)
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, Philip Lienau, Gerhard Siemeister, Karsten Denner, Rolf Bohlmann, Hans Briem, Ildiko Terebesi, Ulf Bömer, Martina Schäfer, Stuart Ince, Dominik Mumberg, Arne Scholz, Raquel Izumi, Stuart Hwang, Franz von Nussbaum
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. Journal of medicinal chemistry 64 (15) (2021)
Markus Berger, Lars Wortmann, Philipp Buchgraber, Ulrich Lücking, Sabine Zitzmann-Kolbe, Antje M Wengner, Benjamin Bader, Ulf Bömer, Hans Briem, Knut Eis, Hartmut Rehwinkel, Florian Bartels, Dieter Moosmayer, Uwe Eberspächer, Philip Lienau, Stefanie Hammer, Christoph A Schatz, Qiuwen Wang, Qi Wang, Dominik Mumberg, Carl Friedrich Nising, Gerhard Siemeister
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. Journal of medicinal chemistry 64 (17) (2021)
Emilie Boulard, Vivien Zibulski, Luisa Oertel, Philip Lienau, Martina Schäfer, Ursula Ganzer, Ulrich Lücking
Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties. Chemistry (Weinheim an der Bergstrasse, Germany) 26 (19) (2020)
Ulrich Lücking, Lars Wortmann, Antje M Wengner, Julien Lefranc, Philip Lienau, Hans Briem, Gerhard Siemeister, Ulf Bömer, Karsten Denner, Martina Schäfer, Marcus Koppitz, Knut Eis, Florian Bartels, Benjamin Bader, Wilhelm Bone, Dieter Moosmayer, Simon J Holton, Uwe Eberspächer, Joanna Grudzinska-Goebel, Christoph Schatz, Gesa Deeg, Dominik Mumberg, Franz von Nussbaum
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. Journal of medicinal chemistry 63 (13) (2020)
Stephanie Greed, Edward L Briggs, Fahima I M Idiris, Andrew J P White, Ulrich Lücking, James A Bull
Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur-Fluorine Exchange (SuFEx) Reaction. Chemistry (Weinheim an der Bergstrasse, Germany) 26 (55) (2020)
Antje M Wengner, Gerhard Siemeister, Ulrich Lücking, Julien Lefranc, Lars Wortmann, Philip Lienau, Benjamin Bader, Ulf Bömer, Dieter Moosmayer, Uwe Eberspächer, Sven Golfier, Christoph A Schatz, Simon J Baumgart, Bernard Haendler, Pascale Lejeune, Andreas Schlicker, Franz von Nussbaum, Michael Brands, Karl Ziegelbauer, Dominik Mumberg
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models. Molecular cancer therapeutics 19 (1) (2019)
Flavia Izzo, Martina Schäfer, Philip Lienau, Ursula Ganzer, Robert A Stockman, Ulrich Lücking
Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides. Chemistry (Weinheim an der Bergstrasse, Germany) 24 (37) (2018)
Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk Kosemund, Rolf Bohlmann, Hans Briem, Ildiko Terebesi, Kirstin Meyer, Katja Prelle, Karsten Denner, Ulf Bömer, Martina Schäfer, Knut Eis, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Bert Klebl, Axel Choidas, Peter Nussbaumer, Matthias Baumann, Carsten Schultz-Fademrecht, Gerd Rühter, Jan Eickhoff, Michael Brands
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem 12 (21) (2017)
Flavia Izzo, Martina Schäfer, Robert A Stockman, Ulrich Lücking
A New, Practical One-Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides. Chemistry (Weinheim an der Bergstrasse, Germany) 23 (60) (2017)

Ulrich Lücking.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ulrich Lücking